Office of Research
Clinical Trials

TRI611 in ALK Positive NSCLC

This is a Phase 1/2 study testing an oral drug called TRI-611 in adults with ALK-positive non-small cell lung cancer. The study has two parts. Part 1 finds the safest dose by giving increasing doses to small groups of participants. Part 2 tests how well the chosen dose works in three groups: people who had no prior ALK drugs, people who had several prior ALK drugs including lorlatinib and neladalkib, and people with intermediate prior treatment histories. Participants take TRI-611 daily as long as it helps and side effects are tolerable. They will visit the clinic about seven times in the first three months, then once at the start of each 28-day treatment cycle, and will keep a diary of doses. Main goals are to assess safety and side effects, pick a recommended dose, and measure tumor response and how long responses last. Some outcomes (like survival and duration of response) will be followed for up to about five years.

This study may be appropriate for those with: Metastatic Cancer

Study of Ipatasertib with Chemoradiation for Head and Neck Cancer

This study is testing if a new drug, ipatasertib, can improve treatment when added to the usual chemotherapy and radiation for advanced head and neck cancer. Ipatasertib could help stop cancer growth by targeting specific proteins in cancer cells. The study aims to find the best dosage alongside existing treatments. It's primarily for patients with advanced stages of head and neck squamous cell carcinoma. Participants must be 18 or older, able to swallow pills, and meet certain health criteria. The study examines safety, necessary dosage, and treatment effectiveness. Patients will receive ipatasertib and typical cancer treatments over a set schedule and undergo various imaging tests. After treatment, they'll be monitored periodically up to two years. This research hopes to improve survival rates and better control cancer growth through this novel treatment combination.

This study may be appropriate for those with: Newly Diagnosed Cancer

Letrozole Study in Recurrent High Grade Gliomas

Patients will receive up to 20 mg of letrozole orally each day both before and after surgical resection. The primary endpoint of this study is the measurement of tumoral bioavailability of letrozole.

This study may be appropriate for those with: Recurrent Cancer

Study on BMX-001 for Reducing Mouth Sores in Head and Neck Cancer Patients

This research study is looking at whether a new drug, BMX-001, can help reduce mouth sores for patients receiving chemoradiation therapy for head and neck cancer. Mouth sores can be painful and make swallowing difficult. The study is for patients who are receiving standard cancer treatment with radiation and the drug cisplatin. The patients will be divided into two groups: one will receive a placebo, while the other group will get BMX-001. Both groups will follow the usual symptom management and will be monitored closely. This study aims to see if BMX-001 can effectively reduce the severity and duration of mouth sores better than usual care alone. Patients' progress will be followed even after the treatment ends, up to 24 months, to gather comprehensive results.

This study may be appropriate for those with: Metastatic Cancer

Investigating NBTXR3 and Radiation for Head and Neck Cancer

This study is testing a treatment called NBTXR3 to see how well it works when combined with radiation therapy, compared to just using radiation therapy with or without a drug called cetuximab. The research is focused on elderly patients who have advanced head and neck squamous cell cancer but cannot undergo platinum-based chemotherapy. Participants will be randomly assigned to two groups; one will receive NBTXR3 with radiation therapy, and the other will receive radiation therapy alone or with cetuximab as chosen by their doctor. The goal is to track how long patients live without their cancer getting worse and overall survival, among other measures. The treatment happens over 7 weeks, with a series of follow-up visits planned afterward.

This study may be appropriate for those with: Metastatic Cancer

Amivantamab Versus Cetuximab in cSCC

This study is testing a new treatment approach for people with cutaneous squamous cell skin cancer that has come back or spread and who have weakened immune systems. Participants are placed into one of two groups. One group gets amivantamab given under the skin together with hyaluronidase to help the drug stay in the body longer. The other group gets cetuximab given into a vein. Treatment is given in 28-day cycles for up to about 24 cycles unless the cancer gets worse or side effects are too severe. Doctors will check safety, how well the cancer responds, and how long people live without cancer growth. Blood tests and scans will be done throughout treatment, and some patients will be followed afterward for years. The study also collects samples for future research.

This study may be appropriate for those with: Metastatic Cancer

Studying Whether Tranexamic Acid Improves Visualization and Recovery in Rotator Cuff Surgery

This study is testing whether adding a small amount of tranexamic acid (TXA), a medication that helps reduce bleeding, to the irrigation fluid used during shoulder arthroscopy can improve the clarity of the surgical view and affect early recovery. When surgeons operate with a camera inside the shoulder, bleeding can cloud the view, making surgery more difficult. TXA might help reduce this bleeding. Adults who are scheduled for arthroscopic rotator cuff repair may be invited to join. After giving consent, patients are randomly assigned to one of two groups: Standard saline irrigation, or Saline irrigation with a low dose of TXA mixed in. Neither the patient nor the surgeon will know which one is used to keep the study fair. The surgery is performed using the usual minimally invasive technique. The video from the procedure is recorded so that surgeons can later rate how clear the view was at different points in the operation. After surgery, patients will have their shoulder movement checked, complete short surveys, measure pain at 8, 24, and 48 hours, and have their swelling measured. Doctors will also review the medical record for information such as operative time, bleeding, hemoglobin changes, and any complications. Patients continue routine clinic follow‑up at 6 weeks and then at 3, 6, 12, and 24 months, completing questionnaires about pain, function, and health. All visits are part of standard postoperative care; no extra visits are required. The purpose of this double‑blind study is to find out whether TXA can safely improve visualization during surgery and possibly help with pain control or reduce complications. The results may help guide future shoulder surgery practices.

BLU 263 ISM Treatment Study

This study tests BLU-263 (elenestinib) versus placebo in people with indolent systemic mastocytosis whose symptoms are not controlled by usual medicines. Participants continue symptom-directed therapy (like antihistamines, proton-pump inhibitors, cromolyn, or corticosteroids) while getting either BLU-263 or placebo. The trial has several parts: short-term randomized blinded parts to measure symptom change and safety at about 13 or 49 weeks, plus an open-label long-term part where participants can continue BLU-263 for up to 5 years to monitor ongoing safety and benefit. Some groups enroll people who previously took a KIT inhibitor and special pharmacokinetic groups check how the drug behaves in the body. Main measures include changes in a validated symptom score, safety events, blood tryptase and KIT D816V levels, bone marrow mast cells, quality of life, anaphylaxis rate, and bone health.

Targeted Therapies Crohns Disease

This is a Phase 2, randomized study testing several targeted medicines for adults with moderate to severe Crohn's disease. About 540 people will be enrolled worldwide and will be randomly assigned to one of the available study treatments. The medicines being tested include risankizumab, trosunilimab, and ABBV-8736, given by injection under the skin or by vein infusion depending on the drug. The main goal is to see how many participants reach endoscopic remission at Week 12. Participants will have regular clinic visits, blood tests, endoscopies, safety checks, questionnaires, and a daily diary to track symptoms and side effects.

Treprostinil for PH ILD Study

This is a Phase 3 randomized, double blind, placebo controlled study testing an inhaled medicine called treprostinil palmitil inhalation powder (TPIP) in adults who have pulmonary hypertension from fibrotic interstitial lung disease. Participants will take TPIP or a matching placebo once daily for 24 weeks. The main goal is to see if TPIP improves exercise ability measured by the six minute walk test at 24 weeks. The study also looks at clinical worsening events, major illness or death, a blood marker of heart strain (NT proBNP), symptom scores, and blood drug levels. People must have their lung scarring confirmed by CT and pulmonary hypertension confirmed by right heart catheterization. Some heart, lung, clotting, smoking, allergy, or other health problems will prevent participation. Side effects may include cough, throat irritation, headache, flushing, nausea, dizziness and low blood pressure. Results will help show whether daily TPIP is an effective and safe treatment for this group of patients.

Contact UCCC CTO for Study Activation

Specific study details/protocols can be provided upon request

Afimkibart in Moderate Severe UC

This Phase 3 randomized study tests Afimkibart (RO7790121), an investigational antibody, versus placebo as a short induction treatment for people with moderately to severely active ulcerative colitis. The main goal is to see how many participants reach clinical remission at Week 12 and to measure healing of the colon with endoscopy and tissue tests. The study also looks at early symptom change (Week 2), pain, urgency, fatigue, quality of life, and safety up to about 30 weeks. Eligible adults must weigh at least 40 kg, be up to date on cancer screening, and have tried but not benefited from at least one standard UC therapy. People with certain infections, recent cancers, specific types of colitis, pregnancy, or prior anti‑TL1A treatment are not allowed to join.

Freiermuth ALTO

Decrease the overall morphine milliequivalents administered to patients who present with femoral fracture or shoulder dislocation by 10% through expanded utilization of ultrasound-guided local anesthetic administration. Objective 1: By the end of year 2, 50% of faculty and residents will have performed a nerve block for one of the targeted conditions or completed training utilizing models through educational sessions led by ultrasound fellowship trained faculty Objective 2: Utilize research staff to screen the ED for eligible patients and remind the treatment team of protocols for ultrasound-guided blocks to increase uptake Objective 3: By the end of the project, perform nerve blocks for at least 50% of patients seen for femur fractures or shoulder dislocations, for a total of 311 patients treated Objective 4: Quarterly assess differences in amount of morphine milliequivalents administered to patients for femur fractures and shoulder dislocations among those who received a nerve block compared to those that did not to monitor impact of the program and guide educational and informational initiatives

Anticoagulation in ICH Survivors

The Anticoagulation in Intracerebral Hemorrhage Survivors for Stroke and recovery study is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and high risk non valvular AF. A total of 700 patients, age 18 or older with a first ever ICH 14-120 days before entry will be randomized in a 1:1 ratio to receive apixaban ( 5 mg tablet twice daily or 2.5 mg tablets twice daily for patients meeting standard dose adjustment requirements) or aspirin (81 mg tablet once daily).

Brain and spine imaging before and after neck surgery for instability

This research study is looking at how advanced MRI scans can show changes in the brainstem and upper spine in people with craniocervical instability or a condition called basilar invagination. Participants will have MRI scans before surgery and again after surgery as part of their regular care, with one additional special scan. Researchers will compare these images to see how the spine and brainstem change after treatment and whether these changes relate to symptoms and recovery. The goal is to improve how doctors measure treatment success and better understand which patients may benefit from surgery.

HNSCC Longitudinal Multiomic Study

This is a non‑interventional, forward‑looking study that will collect blood and tumor tissue from adults with metastatic or unresectable recurrent head and neck squamous cell carcinoma who are starting first‑line anti‑PD‑1 or anti‑PD‑L1 therapy as part of usual care. Samples will be tested using next‑generation sequencing (NGS), circulating tumor DNA (ctDNA) assays, RNA and immune profiling, and other multiomic techniques. Collections occur at baseline and at multiple time points during treatment and follow up. The goal is to find biomarkers that help predict who will benefit from treatment, understand how cancers become resistant, and link biomarker changes to real‑world outcomes like survival and time to next treatment. Participants are followed for up to five years; no experimental treatments are provided as part of the study.

This study may be appropriate for those with: Metastatic Cancer

Lumateperone Pediatric Bipolar Study

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study testing lumateperone in children and adolescents aged 10-17 who have bipolar I or II disorder and are currently in a major depressive episode without psychosis. After a screening period (up to 2 weeks) to confirm eligibility, participants are randomly assigned 1:1 to receive either lumateperone or placebo for 6 weeks while neither participants nor study staff know which treatment is given. About one week after the last dose, patients return for a safety follow-up visit. The main goal is to see if lumateperone improves depressive symptoms at week 6 (measured by a standard depression rating scale) and to monitor safety. Key eligibility points include a confirmed bipolar diagnosis, a recent depressive episode of at least 4 weeks, a history of at least one manic or hypomanic episode, and no high suicide risk or recent manic hospitalization.

Studying Airway Cells in the Lab

Adults having airway surgery may allow small cell samples to be collected and grown in the lab. This research helps scientists study airway diseases and test new treatments but does not change patient care.

Amivantamab added to carboplatin and pembrolizumab vs standard platinum regimens in treatment‑naive R/M HNSCC

This study is to see how well a treatment that includes amivantamab, pembrolizumab and carboplatin works compared to a different treatment that includes 5-FU, pembrolizumab and platinum (carboplatin or cisplatin) therapy. 5-FU, pembrolizumab and platinum (carboplatin or cisplatin) are already used together to treat recurrent/metastatic head and neck squamous cell carcinoma.

This study may be appropriate for those with: Metastatic Cancer

Cyclic Irrigation Expanded Access

This expanded access program offers the VT-X7 system, which delivers vancomycin and tobramycin by cyclic irrigation, to people having exchange surgery to treat a prosthetic joint infection (PJI) of the hip or knee who lack other treatment options. Eligible people are adults 22 to 84 years old who are scheduled for implant removal and who have a confirmed PJI. The program is for patients who may have failed prior exchange surgery. Certain people are not allowed to join, including those with recent bloodstream infection, infection in more than one joint, severe kidney disease, pregnancy, known allergies to the study antibiotics or certain implant materials, active cancer chemotherapy, high dose steroids, some immune problems, recent substance abuse, or other issues that would make study participation unsafe. Treatment involves the surgical removal of the prosthesis and use of the VT-X7 irrigation system during the exchange procedure, with hospital care and follow-up as directed by the study site. The aim is to give access to this antibiotic irrigation approach and to observe how well it is tolerated and works for these patients.

Understanding Social Factors and Infant Health Outcomes

This research study is trying to better understand how social factors like housing, income, transportation, and access to health care may affect infant health. The study includes people who give birth at University Hospital. Participants are asked to complete a survey after delivery. The information collected will be used to learn why some communities have higher rates of premature birth or infant death and to help guide future programs to improve infant health. There is no cost or risk to take part, and participation helps improve understanding of infant health in the community.

Mobile Intervention for Teen Suicide

This study is a double-blind, randomized pilot trial testing two smartphone-based digital programs to lower suicidal thoughts in teens. About 114 adolescents (ages 13-17) who were recently hospitalized after a suicide attempt or who have suicidal thoughts with a past attempt will join with a parent or guardian. Teens and parents, and the research staff who assess them, will not know which digital program the teen receives. The main goal is to see if suicidal thoughts improve over 12 weeks using a standard suicide ideation scale. Teens must have a smartphone and agree to allow one year of medical record review to track any suicide attempts after enrollment. The study screens out teens who are acutely intoxicated, in other similar trials, unable to follow procedures, have serious medical/psychiatric issues that make participation unsafe, or who will be transferred to another inpatient bed at discharge.

Understanding genetic Parkinson's disease

This study looks at people with a rare genetic form of Parkinson's disease and their family members. Researchers collect samples like blood, spinal fluid, and skin to better understand how the disease develops. The goal is to improve understanding of Parkinson's disease causes.

Icalcaprant in Bipolar Depression

This research tests an experimental pill called icalcaprant to treat depressive episodes in adults with bipolar I or II disorder. About 195 adults will be randomly assigned to one of three groups and will take either icalcaprant or a matching placebo once a day for 6 weeks. Neither participants nor staff will know who gets the real drug. After treatment, participants will have a 4-week safety follow-up. The study checks whether depression symptoms improve and records any side effects through medical assessments, blood tests, and questionnaires. Visits occur at study clinics and the number and schedule of visits depend on study procedures at each site.

Hypotension in PDD and DLB

Is hypotension the mechanism behind cognitive fluctuations in Parkinson's disease dementia and dementia with Lewy Bodies? The aim of the study is tp determine if the cortical electroencephalographic signatures of cognitive fluctuations are present in PDD and DLB patients with OH. We will use a tilt table test to determine if PDD/DLB patients with OH may have a differential electroencephalographic pattern than those without OH. Hypothesis: PDD and DLB patients with OH will have dominant frequency variability between alpha (8.0-12.0 Hz) and pre-alpha (5.5-7.5 Hz) bands compared with patients without OH.

Testing a New Combination Therapy for Advanced Lung Cancer

This study is looking at a new treatment combination for people with advanced lung cancer who have stopped responding to typical immune checkpoint inhibitors. The new combination includes the drugs N-803, tislelizumab, and docetaxel vs. just docetaxel alone, to see which is more effective in extending patients' lives. Adults 18 or older with this specific type of cancer could participate if they meet certain health requirements. Key aspects include the ability to follow the study procedures, managing contraception requirements, and having a specific level of health for various bodily functions. Some individuals will not qualify if they have recent treatments that conflict with the new drugs, have severe allergies to study drugs, or other significant health concerns.

This study may be appropriate for those with: Metastatic Cancer

Understanding chronic sinus and nasal inflammation

This research aims to learn more about conditions that cause long-lasting sinus and nasal inflammation, such as chronic sinusitis and allergies. People already receiving routine care may be asked to provide small samples of nasal mucus, blood, or tissue during regular clinic visits. Researchers will compare these samples with symptoms and treatment results over time to understand why some patients respond better to medical treatments than others. The goal is to support more personalized care in the future.

Heart Health Screening During Cancer Care

The study looks at CT scans already done for radiation planning to see if there are signs of heart disease. Adults receiving curative radiation may join. Participation involves surveys and sharing scan findings with doctors. This may help find heart disease earlier.

Study of Rilvegostomig vs. Pembrolizumab with Chemotherapy for Lung Cancer

This study is testing two treatments for people with a specific type of lung cancer called metastatic squamous non-small cell lung cancer (NSCLC). It's for patients whose tumors test positive for a marker called PD-L1. The main goal is to see if a new drug, rilvegostomig, combined with chemotherapy, helps people live longer or stop their cancer from progressing more than the standard treatment, pembrolizumab, combined with chemotherapy. Patients will be randomly placed into either treatment group and both will be blind to which they are receiving to ensure fair results. The study will check how well the treatments work over approximately five years, looking specifically at survival rates and the control over cancer growth and spread. Safety and side effects are also being monitored.

This study may be appropriate for those with: Metastatic Cancer

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study aims to determine whether rectal cancer's response to treatment is the same when patients receive chemotherapy alone before limited surgery versus when they receive both chemotherapy and radiation therapy before limited surgery, and if omitting radiation therapy improves quality of life.

This study may be appropriate for those with: Newly Diagnosed Cancer

Understanding Swallowing Exercises

Healthy adults complete swallowing and tongue exercises during a single x-ray swallow study visit. The goal is to understand how these exercises move swallowing muscles.

Comparing Two Biceps Tenodesis Techniques to Understand Recovery and Shoulder Function

This study compares two common ways of performing biceps tenodesis, a surgery used to treat shoulder pain caused by problems with the biceps tendon. One method, done by Dr. Grawe, uses an arthroscope and repairs the tendon above the pectoral muscle (arthroscopic supra‑pectoral). The other method, used by Dr. Utz, Dr. Summers, and Dr. Branam, uses an open incision below the muscle (open sub‑pectoral). Both are standard procedures used widely in shoulder surgery. Adults who are advised to undergo biceps tenodesis may be invited to participate. After agreeing to join the study, patients will complete short questionnaires about shoulder function and general health, and their shoulder motion will be measured. The type of surgery they receive will be based on the surgeon performing the procedure-not by randomization. After surgery, participants return for follow‑up visits at 6 weeks and at 3, 6, 12, and 24 months. At these visits, doctors check healing, shoulder movement, and symptoms. Patients also complete questionnaires to track pain and shoulder function. A routine ultrasound at the 3‑month visit helps evaluate how the tendon is healing. The study also includes a scar assessment to understand patient satisfaction with the appearance of their incision. The purpose of the study is to learn whether one surgical technique leads to better recovery, improved strength, less pain, or better cosmetic results. Both surgeries are standard treatments and pose no additional risks or costs beyond normal care. The information learned will help guide future patients and surgeons in choosing the most effective approach for biceps tendon problems.

Comparing Effectiveness of Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

This phase II study evaluates the effectiveness of mosunetuzumab versus rituximab, the standard treatment, in extending survival for patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Both mosunetuzumab and rituximab are monoclonal antibodies targeting the CD20 protein on B cells and certain cancer cells, potentially enhancing the immune system's ability to destroy cancer cells. The trial aims to determine if mosunetuzumab offers a superior survival benefit compared to rituximab for individuals with NLPHL.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Empasiprubart versus IVIg in CIDP

This Phase 3 study compares an investigational drug called empasiprubart with standard intravenous immunoglobulin (IVIg) in adults who have CIDP and who have previously responded to IVIg. In Part A (24 weeks) participants are randomly assigned in a double blind way to receive either empasiprubart plus a placebo that looks like IVIg or IVIg plus a placebo that looks like empasiprubart. After finishing Part A, all participants may enter Part B and receive empasiprubart for up to 96 weeks. The main goal is to see whether patients improve by at least one point on a disability scale (aINCAT) at week 24. The study also tracks strength, grip, walking time, patient reported quality of life and fatigue, work impact, antibody responses to the study drug, drug levels in the blood, and any side effects over the full study period.

PD GENEration Genetic Registry

This study collects genetic test results and leftover DNA from people with Parkinson's to build a central, secure resource for future research. Adults who have a probable Parkinson's diagnosis and agree to genetic testing can join. Participants allow their data to be stored for research and can choose to be told their results for several PD-related genes. The study also provides genetic counseling so people can understand what their results mean. It is an observational, one-time study (cross-sectional) meant to find how common certain gene changes are and to help researchers studying Parkinson's. There is no drug or treatment given; the study involves surveys, genetic testing, and storing DNA for future studies.

Cilostazol Prevent Recurrent Stroke

This is a phase 3, randomized trial testing whether adding the medicine cilostazol to a person's current antiplatelet drug (either aspirin or clopidogrel) helps prevent another stroke, heart attack, or death from blood vessel disease. People who had a stroke or mini‑stroke (TIA) in the past 180 days and who are taking one antiplatelet drug may join. Participants will be followed for up to 4 years to see how long it takes for major events (stroke, heart attack, or vascular death) to occur. The study will also track time to ischemic stroke and the time to any major bleeding events. People with a recent spontaneous brain bleed, significant heart failure, or a life expectancy under 6 months are not eligible. The trial is not yet recruiting.

TQR-84 (Placebo Study)

Patients will be told they are receiving either a novel medication (TQR-84) or placebo. However, all participants will receive IR-CD/LD. We will evaluate the differences on motor improvement after levodopa introduction, as measured by the motor subscale of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS-III),13 between a positive framework (to enhance expectations) compared to a neutral framework (to dampen expectations).

Evaluating Nipocalimab for Reducing Risk of Severe HDFN in Pregnancies

This study aims to determine the effectiveness of a drug called nipocalimab in pregnant women who are at risk for severe Hemolytic Disease of the Fetus and Newborn (HDFN), a condition where the mother's antibodies attack the baby's red blood cells, leading to anemia in the baby. Anemia can cause serious problems for unborn babies, including death. The study compares nipocalimab to a placebo to see if it can safely reduce these risks and improve outcomes like preventing fetal loss or life-threatening conditions. Participants will be randomly assigned to receive either the drug or a placebo and will be monitored throughout their pregnancies and after their babies are born until they are at least 24 weeks old.

Dose Escalation/​Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 alone or with Pembrolizumab

This clinical trial is assessing a new treatment, called TEV-56278, which is being tested alone and in combination with another drug called Pembrolizumab. This trial focuses on individuals who have advanced solid tumors. These types of tumors might be resistant to standard treatments or have not responded well to them. This study, conducted by Teva Branded Pharmaceutical Products, aims to find a safe and effective dosage of TEV-56278. It hopes to determine whether it can effectively inhibit tumor growth when used on its own or together with Pembrolizumab. Participants will be observed for any side effects and to see how well the tumor responds to the treatment. The study duration includes being treated for up to one year and followed for up to another year, totaling a possible two years per participant. The trial is ongoing, offering treatment possibilities for those who meet specific inclusion criteria, including having previously received treatment for their tumor and having a life expectancy of at least 12 weeks.

This study may be appropriate for those with: Metastatic Cancer

How Straw Exercises Affect the Voice

Healthy adult singers will try different straw-based voice warm-ups. Researchers will measure how the voice responds to different straw types. There is no medical benefit, but the study may inform voice training.

Studying a Switch in Treatment for Relapsing Multiple Sclerosis

This study is testing whether a daily oral medicine called remibrutinib works as well as the current treatment, ocrelizumab, for people with relapsing multiple sclerosis. People who have been on ocrelizumab for at least 18 months and are between 40 and 70 years old may join. The study will look at how MS changes over time using MRI scans, physical tests, and symptom reports. Participants may receive remibrutinib or continue ocrelizumab for up to two years, and those who finish this part may continue on remibrutinib for another two years. The study aims to learn whether switching to remibrutinib is safe, effective, and easier for patients.

Understanding Flare-Ups in Chronic Sinusitis

This study aims to understand why people with chronic sinus problems sometimes experience sudden flare-ups. Adults with chronic sinusitis will have nasal samples taken during a flare-up and again about a month later. The study does not change medical care but may help improve future treatments.

ALTO ED Integrative Health Referrals

This study tests whether routinely offering ED patients a referral to integrative health services increases use of nonpharmacologic options and reduces opioid prescribing and opioid consumption. Qualifying ED patients (age ≥18) presenting with low back pain, headache, abdominal pain, certain mental health conditions, or suspected substance use disorder will be offered a referral to the Osher Center for Integrative Health. Services available include acupuncture, mindfulness therapy, music therapy, massage, movement therapies (tai chi, yoga), lifestyle coaching, and nutrition education. The intervention is operationalized by adding the Osher Center referral to the ED preference list in the electronic health record to make it easy for ED clinicians to offer and place referrals. Participants will complete a baseline visit in the ED and a 30-day follow-up phone call to capture referral uptake, opioid prescriptions written, opioid use, pain and symptom measures, and patient experience. Patients who are pregnant, prisoners, unable to consent, actively suicidal/on psychiatric hold, febrile, trauma activations, or with altered mental status are excluded. Total participation time is 30 days (baseline plus one follow-up). The primary goals are to increase integrative health referrals and uptake and to decrease opioid prescribing and patient-reported opioid consumption after ED discharge.

KarXT for Teen Schizophrenia

This is a randomized, double-blind, placebo-controlled Phase 3 study testing KarXT in adolescents (13–17 years) with schizophrenia. After screening and confirmation of diagnosis, participants are randomly assigned to receive KarXT or placebo. The main goal is to see if KarXT reduces psychotic symptoms compared with placebo after about five weeks of treatment. Safety and overall clinical improvement will also be measured. The study checks symptom scales and global functioning during the treatment period. People with other major psychiatric disorders, significant medical or neurological conditions, known intellectual disability, severe liver problems, or very high blood pressure are not eligible.

Radiation With Cetuximab or Chemotherapy

This phase 3 trial compares two treatments given with high-precision radiation therapy (IMRT) for people with advanced head and neck cancer who cannot take cisplatin. Patients are randomly placed into one of two groups. One group gets weekly cetuximab (a drug that targets the EGFR protein on some cancer cells) together with 35 daily radiation treatments over about 7 weeks. The other group gets weekly carboplatin and paclitaxel chemotherapy together with the same radiation schedule. Patients have scans and blood tests during the study and are followed after treatment at 30 days, then at 4, 6, 12, 18, 24, 30, and 36 months and then yearly. The main goal is to compare progression-free survival between the two groups. Secondary goals include comparing overall survival, side effects, where the cancer returns if it does, and changes in eating and speaking function.

This study may be appropriate for those with: Metastatic Cancer

Treatment for adults with anxiety

The purpose of this study is to look at two medications, escitalopram and duloxetine, in adults with anxiety (between the ages of 18 and 50) in addition to, two add on medications, clonazepam or pregabalin. The study doctors are trying to understand which medication(s) will work best

Beat AML Biomarker Treatment Trial

This study is a master protocol that screens people with acute myeloid leukemia (AML) using rapid lab and genomic testing. Based on the test results, each person is placed into one of several smaller treatment studies that test targeted, investigational therapies or drug combinations. The goal is to complete testing and assign patients to a matched treatment within 7 days, and then follow treatment responses and safety over time. The trial includes groups for newly diagnosed patients, relapsed or refractory patients, and a marker-negative group for those who don't match a specific marker. Some sub-studies focus on older adults or patients who cannot or choose not to get intensive chemotherapy. Follow-up can continue for years to track responses and changes in disease over time.

This study may be appropriate for those with: Newly Diagnosed Cancer

INEBILIZUMAB IN ANTI-NMDA ENCEPHALITIS

There are currently no medicinal products approved for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, a rare disease. NMDAR encephalitis is a life-threatening, antibody-mediated autoimmune disorder of the central nervous system. Standard of care includes high-dose corticosteroids AND either intravenous immunoglobulin (IVIg) OR plasmapheresis. However, as many as 47% of patients may fail to respond to initial treatment at 4 weeks; thus, there is a high unmet medical need for more effective therapies. The pathogenesis of NMDAR encephalitis suggests that B cell depletion may be an effective avenue for therapeutic intervention. The anti-CD19 B cell-depleting activity of inebilizumab suggests that it may provide benefit as treatment for NMDAR encephalitis. This study aims to define the efficacy and safety of inebilizumab in reducing the level of disability in patients with NMDAR encephalitis as measured by modified Rankin score (mRS). If you think that you might have a potential participant contact the ExTINGUISH hotline 844-4BRAIN5 (844-427-2465)

Studying Airway Bacteria in Stenosis

Adults undergoing airway surgery will have airway samples collected to study bacteria that may affect healing and disease.

Videofluoroscopic Swallowing Norms

This study will use videofluoroscopy (a moving X-ray of swallowing) to measure how people of different ages swallow. The team will test about 280 healthy adults across the adult age span and will also collect data from three clinical groups at risk for swallowing problems: people with Parkinson disease, people with COPD, and people recently having had a stroke. The goal is to build clear normal ranges for swallowing measures (like airway protection, residue left after swallowing, timing of airway closure, and how well the throat squeezes) and to find practical cutoff points that help tell normal from disordered swallowing. The results aim to help clinicians interpret swallowing tests more reliably and guide diagnosis and treatment decisions.

Bladder Preservation Immunoradiation

This Phase II study tests whether combining the immune drug pembrolizumab with radiation therapy can allow people with muscle invasive bladder cancer to keep their bladder after the tumor has already shrunk from pre-surgery chemotherapy. Eligible patients have an excellent clinical response after neoadjuvant chemotherapy and will receive daily photon radiation to the bladder Monday through Friday for up to about 4 weeks while also getting pembrolizumab through an IV every 3 weeks. Before joining, patients have had a TURBT (a bladder tumor biopsy/removal procedure) and staging scans. The study tracks how long patients keep their bladder without cancer returning, whether they later need bladder removal (salvage cystectomy), survival outcomes, side effects, and patient-reported symptoms. Blood, urine, and tissue samples will be stored for future research. After finishing treatment, participants are followed regularly for up to 5 years.

This study may be appropriate for those with: Newly Diagnosed Cancer

Comparing Two Surgical Options for Stabilizing Metastatic Bone Disease in the Upper Thigh (PERFORM)

The PERFORM study is a major international research trial comparing two ways of treating cancer‑related bone disease in the upper part of the thigh bone (proximal femur). Some patients develop weak or broken bones in this area when cancer spreads to the skeleton, and surgery is often needed to help them walk safely and reduce pain. The study compares two surgical options: Resection and reconstruction - removing the damaged section of bone and replacing it with an implant. Internal fixation - strengthening the bone using plates, screws, or a rod placed inside the bone. Patients who qualify will be randomly assigned to one of the two procedures. Doctors want to know which option helps patients live longer, stay mobile, and spend more days at home during the year after surgery. The study also measures quality of life, physical function, pain levels, and time spent in hospitals or care facilities. About 334 patients from hospitals across Canada, the U.S., and other countries will participate. Everyone will be followed for one year after their surgery, with check‑ins and questionnaires at several time points. All surgeries and follow‑up visits are standard medical care. The goal of PERFORM is to provide strong evidence to guide surgeons on the best treatment for people with metastatic bone disease in the femur. By comparing these two common surgical approaches, the study will help determine which one offers better long‑term outcomes and quality of life for cancer patients.

AMXT1501 and DFMO With Standard Care

This open-label Phase 1b/2 study tests two oral drugs, AMXT 1501 and DFMO, given together with standard treatments in people with advanced ER+ / HER2- breast cancer or with unresectable or metastatic cutaneous melanoma. AMXT 1501 blocks tumor uptake of polyamines and DFMO lowers polyamine production; together they aim to reduce tumor-supporting molecules and possibly improve responses to standard therapy. In the breast cancer group the combo is given with fulvestrant and capivasertib. In the melanoma group the combo is given with pembrolizumab. The Phase 1b part uses a small dose-escalation plan to find a safe dose for Phase 2. The Phase 2 part will look for signs the treatment controls or shrinks tumors using standard tumor response rules. The study also checks drug levels in blood, changes in tumor tissue and immune genes, and overall safety. About 92 patients may be enrolled across the two groups. Participants will have screening tests, regular clinic visits each treatment cycle (28 days), imaging to measure response, and follow-up visits.

This study may be appropriate for those with: Metastatic Cancer

Using a Blood Test to Tailor Blood‑Clot Prevention After Surgery for Metastatic Bone Disease

Cancer patients with metastatic disease that has spread to the bones are at high risk for blood clots, especially after surgery. This study explores whether using a special blood test called thromboelastography (TEG) can help doctors choose the safest and most effective blood‑thinner medication for each individual patient. Before surgery, a small blood sample is tested using Rapid TEG to see how quickly and strongly the patient's blood forms clots. Based on this test, patients are placed into groups ranging from "low clotting tendency" to "high clotting tendency." Each group has a matching treatment plan to help prevent dangerous blood clots after surgery, using medications like aspirin or low‑molecular‑weight heparin (enoxaparin). All participants also have an ultrasound scan of both legs to check for blood clots before surgery, and a second scan six weeks later. Patients are monitored for signs of deep vein thrombosis (DVT), pulmonary embolism (PE), bleeding, need for transfusion, or return to the operating room. Participants complete short questionnaires measuring physical function, pain, and anxiety before surgery and again at several follow‑up visits through the first year. These help the research team understand how patients feel and function during recovery. No experimental treatments are used-only tests and medications that are already part of standard orthopedic and cancer care. The information learned will help doctors design a larger future study and may lead to more personalized, safer blood‑clot prevention for patients with metastatic bone disease.

New Surgical Tool for Brain and Skull Base Surgery

This research is studying a surgical tool called DuraStat that is used to help close the protective lining around the brain during certain skull base surgeries done through the nose. Sometimes this lining is opened during surgery and needs to be carefully repaired to prevent fluid leaks or infection. The study will follow adults who are already having this type of surgery and need a repair during the procedure. Doctors will look at how well the repair works and how patients heal over time. Follow-up visits are part of normal surgical care, and participation does not require extra procedures beyond standard treatment.

Understanding Drug Delivery to the Inner Ear

During routine ear surgery, small pieces of tissue that would otherwise be thrown away are studied in the lab to improve future hearing treatments.

How eating a meal affects tongue strength and fatigue

This study is exploring how eating a normal meal may cause tongue fatigue and whether this differs by age. Healthy younger and older adults will complete simple tongue strength tasks before and after eating a standardized meal. These tasks help researchers understand how eating affects the muscles used for chewing and swallowing. Participation involves a single visit and does not change medical care. The results may help improve understanding of fatigue related to eating as people age.

Study on IOV-4001 for Advanced Melanoma and NSCLC

This study is the first-in-human study of IOV-4001, a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product. IOV-4001 is expected to have antitumor activity through its capacity to directly target and kill tumor cells in a manner that is similar to non-genome-edited TIL, but with the potential for enhanced antitumor activity due to disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1).

This study may be appropriate for those with: Metastatic Cancer

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with metastatic kidney cancer. Patients will receive 1 of the following 4 treatment options: Nivolumab 240 mg IV 1 q 2 weeks, Nivolumab 480 mg IV 1 q 4 weeks, Pembrolizumab 200 mg IV 1 q 3 weeks and Axitinib 5 mg oral Daily BID, OR Avelumab 10 mg/kg IV 1 q 2 weeks and Axitinib 5 mg oral Daily BID. Those in Arm 2 will also undergo a radical or partial nephrectomy. Efficacy will be measured by determining Overall Survival.

This study may be appropriate for those with: Newly Diagnosed Cancer

Higher Dose Radiation Therapy for Advanced Pancreatic Cancer Trial

This study is exploring if giving higher doses of radiation can help people with advanced pancreatic cancer live longer. Participants must have already undergone 4-6 months of chemotherapy and have stable disease without progression. There are two groups in the study. One group will receive standard treatment, which could include continuing chemotherapy, a normal dose of radiation, or observation. The other group will receive higher doses of radiation over a shorter period to see if it prolongs their survival. Patients will have regular follow-ups and will be checked through blood tests, imaging scans, and tissue biopsies. They are monitored over a period that includes every three-month checkups for two years and then yearly for another three years. This study aims to not only see if survival improves but examine side effects, quality of life, and any changes in disease progression.

This study may be appropriate for those with: Metastatic Cancer

Selective Cytopheretic Device Trial

This study will enroll about 200 adults in intensive care units who have acute kidney injury (AKI) and need continuous kidney replacement therapy (CKRT). Patients are randomly assigned to receive standard CKRT alone or CKRT plus up to ten 24-hour treatments with the Selective Cytopheretic Device (SCD). The SCD is a device used during CKRT that aims to calm overactive white blood cells (neutrophils and monocytes) to reduce inflammation. The main goal is to find out whether adding the SCD lowers the chance of death or needing ongoing dialysis 90 days after starting treatment. Other outcomes include kidney-related events at 90 days, need for dialysis at one year, days alive outside the ICU in the first 28 days, and 28-day death rate. Key rules: participants must be 18-80, have moderate to severe AKI when CKRT starts, have a high C-reactive protein, and have another serious organ problem. People are excluded if they are not expected to survive short-term, already on long-term dialysis, have certain infections or immune problems, are pregnant, or are in other situations that make the study unsafe or not useful. Follow-up includes checks up to 90 days and one year to track kidney recovery and survival.

Brain MRI in Adults with Sickle Cell Disease

The purpose of this study is to see whether inflammation is present in the brains of people with sickle cell disease and whether this inflammation may be a cause of decreased cognition (ability to learn/remember) in people with sickle cell disease. Brain images from people with sickle cell disease will be compared to brain images from people without sickle cell disease.

Testing Abemaciclib with 5-Fluorouracil for Metastatic Colorectal Cancer

This clinical trial is investigating how well two drugs, Abemaciclib and 5-Fluorouracil (5-FU), work together in treating people with colorectal cancer that has spread to other parts of the body and hasn't responded to other treatments. The study aims to discover the safest dose of the drug combination that patients can handle without severe side effects. Participants will take Abemaciclib by mouth twice daily, and receive 5-FU through a vein on specific days during each 28-day cycle. Throughout the study, various samples will be collected to track the effectiveness and side effects of the treatment. After finishing the treatment cycles, participants will be monitored every three months for follow-up. Researchers hope this combination will provide a new option for those with this difficult-to-treat cancer type.

This study may be appropriate for those with: Metastatic Cancer

Using Exam Under Anesthesia to Guide Pelvic Surgery for Partially Unstable (B-Type) Injuries

This study will help surgeons decide how best to treat certain partially unstable pelvic fractures ("B‑Type" injuries). During surgery, doctors perform an exam under anesthesia (EUA) that gently stresses the pelvis to see how stable it is. Based on what the exam shows, some patients will not need fixation, some will need fixation in the front (anterior), and others may benefit from fixation in both the front and back (anterior + posterior). When both surgical choices are reasonable, patients will be randomly assigned to one of the two standard options (front only or front + back). Randomization is a fair way to compare treatments that are both commonly used. The goal is to improve recovery and function, reduce complications like loss of alignment or hardware failure, and avoid unnecessary procedures. After surgery (or nonoperative care if no fixation is needed), participants will return for routine clinic visits with X‑rays at about 6 weeks, 3 months, 6 months, and 12 months. At these visits, doctors will check healing and ask participants to complete short questionnaires about their day‑to‑day function and well‑being. All personal information is kept secure. Consent includes an explanation of privacy protections and what participation involves. This study may help future patients by showing when it is safe to use less surgery and when additional stabilization improves outcomes.

Emergency Contraceptive Metabolism Study

This study looks at why emergency birth control pills sometimes fail for some people and not others. The researchers will give participants a single dose of ulipristal acetate (UPA), the oral emergency contraceptive, and then watch how the body responds. They will use blood tests to measure UPA levels and ultrasound to see whether the ovary releases an egg (ovulation). The main question is whether genetic differences that affect the enzymes that break down UPA change how much drug is in the blood and whether the drug can stop or delay ovulation. Participants will be healthy people aged 18 to 40 with regular, ovulatory menstrual cycles. The study follows one menstrual cycle (about 30 days) and includes screening, the study dose, blood draws, and ultrasound checks. The goal is to better understand who is more likely to have emergency contraceptive failure and to help make emergency contraception work better for everyone.

Pramipexole vs Escitalopram Study

This is a Phase 2, open-label randomized trial that will compare two medicines for depression in people living with HIV: pramipexole extended release and escitalopram. Participants will be randomly assigned to one of the two treatments and followed for about 24 weeks. Study visits will check how participants are feeling, measure depression and thinking skills, and watch for side effects. A smaller optional sub-study will collect and study spinal fluid in up to 36 people to see how treatment affects brain inflammation markers.

AT1501 Kidney Transplant Study

This is a Phase 1b, open-label study that will test AT-1501 in up to 48 people receiving a first kidney transplant. AT-1501 is given with standard transplant medicines: rATG as induction, low-dose corticosteroids, and mycophenolate for maintenance. The study will track safety issues, measure how the drug behaves in the body (drug levels and related measures), and look for signs that it helps prevent rejection. Safety will be followed through the study (about up to 20 months on average). Pharmacokinetic sampling is planned soon after the first dose and again at steady state around Month 3. The study is single-arm, so every participant receives AT-1501 alongside routine transplant care.

Stem Cell Transplant V/S BAT Therapy

This is a Randomized study to compare the efficacy, safety, immunologic effects, and cost-effectiveness of myeloablative and immunoablative therapy followed by autologous hematopoietic stem cell transplant (AHSCT) versus best available therapy (BAT) over 72 months in participants with relapsing MS and continued MS disease activity despite treatment with DMTs.

Comparing Two Surgical Approaches for Repairing Posterior Wall Hip Socket Fractures

This study looks at two ways surgeons repair a specific type of hip fracture called a posterior wall acetabular fracture. Both techniques use metal plates to support the bone as it heals. Participants are randomly assigned to one of the two standard surgical treatments and will have regular checkups with X‑rays for up to one year. The goal is to learn whether one method leads to better healing or recovery.

REAL AF - Catheter Ablation for Treating Atrial Fibrillation

This study looks into how catheter ablation works for treating people who have Paroxysmal or Persistent Atrial Fibrillation. By observing patients, the research team will gather data on how well these technologies help with atrial fibrillation over time, both in terms of effectiveness and safety. During the study, participants will have regular assessments before and after their catheter ablation procedures. The expected benefits are to determine how good these methods are at stopping irregular heart rhythms and ensuring patient safety.

ExoFlo EVs for ARDS Phase III

This Phase III randomized, double-blind, placebo-controlled trial tests an intravenous extracellular vesicle product called ExoFlo (from bone marrow mesenchymal stem cells) in hospitalized adults with moderate-to-severe ARDS. Participants receive either a single IV dose of ExoFlo (15 mL) or a matched placebo and are followed in hospital with assessments and additional follow-up through about Day 61. The main goal is to see if ExoFlo lowers 60-day all-cause mortality compared with placebo. Secondary goals include time to death, ventilator-free days, oxygen-free days, ICU-free days, and the rate of serious adverse events. Key eligibility includes adults 18-75 with ARDS that started within 7 days and meets clinical and imaging criteria; main exclusions include recent major trauma, long prior ventilation (>72 hours), severe liver disease, pregnancy, DNR status, ECMO, or recent investigational treatments.

Inotuzumab With Chemotherapy for Young Adults with Newly Diagnosed B-Cell ALL

This trial tests whether adding the antibody drug inotuzumab ozogamicin to a pediatric-style chemotherapy plan helps young adults (about ages 18-39) with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL). All patients first get a standard induction course of chemo. Those who respond are randomly assigned to either continue the standard multi-course chemotherapy plan or get the same chemotherapy plus inotuzumab given on days 1, 8, and 15 of a 28-day cycle (up to two cycles). The main goals are to confirm the added drug is tolerable and to see if it improves the time patients stay free of relapse or death (event-free survival). The study also looks at overall survival, disease-free survival, how much disease is left after treatment, genetic markers, drug side effects, drug levels, and how well patients take their oral medicines. Treatment can continue for months to years depending on the course, and patients are followed closely for many years after finishing treatment.

This study may be appropriate for those with: Newly Diagnosed Cancer

Cooling Treatment for Patients with Severe Lung Injury

This study looks at whether gently cooling the body can help people with severe lung injury get off the breathing machine sooner. Participants have a serious lung condition called ARDS that makes it hard to breathe. Researchers will compare standard care with a cooling approach that lowers body temperature slightly for two days. The goal is to see if cooling helps the lungs heal faster and improves recovery.

Comparing Two Surgical Approaches for Fixing Posterior Malleolus Fragments in Ankle Fractures

This study looks at two accepted surgical approaches used to repair a specific part of the ankle-the posterior malleolus-in patients who have trimalleolar ankle fractures. In some patients, surgeons directly fix the broken piece of bone in the back of the ankle. In others, surgeons use indirect techniques to reduce and stabilize the fragment without directly exposing it. Both methods are commonly used today, but it is not known which leads to better stability and long‑term recovery. Patients who require surgery and meet the study's criteria will be invited to participate. Before surgery, each person receives standard X‑rays and a CT scan, and fills out questionnaires about their daily function and overall health. During surgery, after the main ankle bones are fixed, the surgeon performs a series of stress tests on the ankle joint to see whether the syndesmosis-the ligaments between the tibia and fibula-needs to be stabilized. These tests are standard and help determine the best treatment for each patient. The surgery itself and all choices about implants, positioning, and fixation are made by the treating surgeon based on their usual clinical practice. After surgery, patients return for checkups at about 6 weeks, 3 months, 6 months, and 12 months. At these visits, patients complete short surveys about pain, activity, and function, and receive routine X‑rays (except at the initial 2‑week wound check). The goal of the study is to find out whether directly fixing the posterior malleolus fragment leads to better ankle stability, fewer complications, and improved function compared with indirect treatment. The study does not add extra costs, procedures, or risks beyond standard care. What we learn may help guide future treatment decisions and improve recovery for patients with this type of ankle fracture.

Testing New Treatment for Residual Cancer in B-cell Lymphoma Patients

This study is testing if a new experimental treatment named cemacabtagene ansegedleucel (or cema-cel for short) can help adults with large B-cell lymphoma, a type of blood cancer. Patients who have already finished one round of regular treatment and are still showing signs of leftover cancer according to a special test are being looked at. The study compares cema-cel treatment versus just watching the patients to see which helps more in preventing cancer events and eliminating leftover cancer cells. Participants must have completed standard initial therapy, be over 18, and meet certain health criteria. Those with recent other cancers or serious current infections, among other things, cannot join. The study will check for various outcomes over several months to see how well cema-cel works and note any side effects.

This study may be appropriate for those with: Newly Diagnosed Cancer